Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision indicator on the page was updated to v3.6.6, replacing the previous v3.6.5.
    Difference
    0.1%
    Check dated 2026-09-01T19:32:36.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    The revision label was updated from v3.6.4 to v3.6.5, indicating a platform update. The study details and user-facing content remain unchanged.
    Difference
    0.1%
    Check dated 2026-08-11T14:50:42.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page shows a new revision label, updating from v3.6.3 to v3.6.4, indicating a deployment of a new build. The underlying study information and content remain unchanged.
    Difference
    0.1%
    Check dated 2026-07-28T05:57:30.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    The revision label in the page footer was updated from v3.6.2 to v3.6.3, signaling a minor maintenance update to the site.
    Difference
    0.1%
    Check dated 2026-07-06T15:48:44.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Page footer revision label updated from v3.6.0 to v3.6.2, indicating a minor platform update to the study details page. This change does not affect the study content or data displayed on the page.
    Difference
    0.1%
    Check dated 2026-06-29T08:53:15.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The page adds recruitment status information and new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) while standardizing the Intervention/Treatment label and updating the revision tag to v3.6.0.
    Difference
    0.5%
    Check dated 2026-06-15T08:31:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.